Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The global challenge of antibiotic resistance demands innovative solutions, and antimicrobial peptides like LL-37 are emerging as powerful contenders. NINGBO INNO PHARMCHEM CO.,LTD. is actively engaged in research that explores the potential of LL-37 to overcome the limitations of conventional antibiotics. The unique properties of LL-37 position it as a promising candidate for a new era in combating resistant bacteria.
LL-37, a key component of the human innate immune system, exhibits a broad spectrum of antimicrobial activity against a wide range of pathogens, including those that have developed resistance to existing drugs. Its mechanism of action differs significantly from traditional antibiotics. Instead of targeting specific bacterial metabolic pathways, LL-37 primarily disrupts bacterial cell membranes through mechanisms like pore formation. Understanding this LL-37 antimicrobial peptide mechanism is crucial for its therapeutic application.
The peptide's ability to oligomerize and form channels in bacterial membranes is central to its effectiveness. This LL-37 channel formation, as elucidated by structural studies, provides a physical means to compromise bacterial integrity. This approach is less prone to the development of resistance compared to mechanisms that target specific intracellular processes. This aligns with the broader goals of antimicrobial peptide research seeking alternative strategies.
Beyond its direct killing of bacteria, LL-37 also possesses immunomodulatory properties that can enhance the host's defense against infection. Its involvement in wound healing and its ability to influence inflammatory responses further expand its therapeutic potential. The diverse LL-37 applications in medicine are continuously being explored, from direct antimicrobial treatments to adjunctive therapies that boost the efficacy of other drugs.
NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to advancing the research and development of LL-37 and similar peptides. By focusing on the LL-37 structure-activity relationship and its LL-37 in innate immunity context, we aim to harness the full therapeutic potential of this remarkable peptide. The fight against antibiotic resistance requires novel approaches, and LL-37 represents a significant stride in that direction.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
